Fig. 2
From: Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
The HRD scores, gene mutations and Kaplan-Meier analysis of progression free survival in training group of EOC. (A) The HRD status. Note: The numbers indicate the HRD score from the two tests. The orange color indicates a positive HRD status obtained using our WES-based scarHRD test. The yellow color indicates a positive HRD status obtained using the Myriad MyChoice® CDx test. The red color indicates BRCA1/2 gene mutations. The green color indicates other DDR gene mutations. (B) Correlation between the WES-based scarHRD score and the Myriad MyChoice® CDx test score. Note: WES-based scarHRD test score is highly correlated with the MyChoice® CDx test score. A MyChoice® CDx test score of 42 is equal to the WES-based scarHRD score of 50 obtained using the linear regression model. (C) PFS of EOC patients stratified by surgical resection status. Note: EOC patients who underwent R0 resection had better PFS than those who underwent R1 resection (p = 0.032, log-rank test). (D) PFS of EOC patients stratified by our WES-based scarHRD test. Note: EOC patients with a positive HRD status had better PFS than those with a negative HRD status (p = 0.002, log-rank test). (E) PFS of EOC patients stratified by Myriad MyChoice® CDx test. Note: EOC patients with a positive HRD status had better PFS than those with a negative HRD status (p = 0.002, log-rank test)